ID
20662
Beskrivning
Documentation Part: Liver Events Assessment An Open Label, Repeat Dose, Dose Escalation Study Conducted in Parkinson's Disease Patients to Characterize the Pharmacokinetics and Effect of Food on Ropinirole Prolonged Release (PR/CR) 12mg Tablets. ClinicalTrials.gov Identifier: NCT00460148 https://clinicaltrials.gov/ct2/show/NCT00460148?term=NCT00460148&rank=1 Responsible Party: GlaxoSmithKline
Länk
https://clinicaltrials.gov/ct2/show/NCT00460148?term=NCT00460148&rank=1
Nyckelord
Versioner (1)
- 2017-03-09 2017-03-09 -
Uppladdad den
9 mars 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Liver Events Assessment Parkinson's Disease Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole NCT00460148
Liver Events Assessment Parkinson's Disease Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole NCT00460148
Beskrivning
Liver Events Assessment
Alias
- UMLS CUI-1
- C1556667
Beskrivning
If Yes, stop investigational product, complete date stopped on Investigational Product form, contact GSK within 24 hours of occurrence, complete Liver Events Form and obtain the following tests: • PK blood sample within 24 hours of last dose (or 3x the investigational product half-life or t1/2). • Hepatitis A: Hepatitis A lgM antibody. • Hepatitis B: Hepatitis B surface antigen and Hepatitis B Core Antibody (lgM). • Hepatitis C: Hepatitis C RNA. • Hepatitis E IgM antibody (if subject resides or has travelled in past 3 months outside the USA or Canada). • Cytomegalovirus IgM antibody (CMV) • EBV (Epstein Barr viral capsid antigen IgM antibody) or if unavailable, obtain heterophile antibody or monospot testing. • CPK (serum creatine phosphokinase) • LDH (lactate dehydrogenase) • Bilirubin fractionation, if bilirubin >1.5xULN The following are only needed when ALT >3xULN and bilirubin >1.5xULN (>35% direct) • Anti-nuclear antibody • Anti-smooth muscle antibody • Type 1 anti-liver kidney microsomal antibodies (if available) • Liver Imaging (ultrasound, magnetic resonance, or computerised tomography)
Datatyp
text
Alias
- UMLS CUI [1,1]
- C0023901
- UMLS CUI [1,2]
- C1556667
Similar models
Liver Events Assessment Parkinson's Disease Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole NCT00460148
C1556667 (UMLS CUI [1,2])